Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
In a phase 3 trial-based cost-effectiveness analysis for advanced breast cancer, treatment with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in the second line rather than the first line ...
SAN ANTONIO — For patients with advanced hormone receptor-positive, HER2-negative breast cancer, health-related quality of life is the same whether they receive CDK4/6 inhibitors in the first or ...
Targeted cancer drugs known as CDK4/6 inhibitors have improved outcomes for patients with advanced or metastatic HR+/HER2- breast cancer, but many patients still eventually relapse and become ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
CDK 4/6 inhibitors are a treatment for hormone receptorpositive (HR-positive), HER2-negative breast cancer that has spread to other parts of the body. They come as pills, and are often given with ...
Primary endpoint met in first randomized Phase 2 study, FOURLIGHT-1, showing a 40% reduction in the risk of disease progression or death with manageable safety profile More than 90% of patients ...
Camizestrant plus CDK4/6 inhibitors improved progression-free survival in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer compared to AI and CDK4/6 inhibitors. The SERENA-6 trial used ...
No significant OS advantage was found among CDK4/6 inhibitors for HR-positive, HER2-negative metastatic breast cancer. Real-world data showed median OS of 54.6 months for Ibrance, 59 months for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results